AstraZeneca and YMCA of the USA (Y-USA) have formed a five-year partnership to address gaps in cancer care by strengthening education in screening and early detection. The collaboration aims to reach 175,000 people across 75 communities nationwide over the first two years. This initiative seeks to increase awareness of cancer screening and support survivors through evidence-based programs.

The partnership was announced at the Aspen Ideas: Health conference. It leverages Y-USA’s 175-year legacy in community health and AstraZeneca’s ambition to eliminate cancer as a cause of death. The initial focus is on tailored, community-driven solutions to improve early detection rates and support individuals navigating their cancer journey.

Key Objectives and Reach

The collaboration targets significant disparities in cancer screening rates across different demographics. By combining AstraZeneca’s global expertise in life-changing innovations with the YMCA’s expansive community reach, the partners aim to transform the nation’s approach to cancer care.

Leadership Perspectives

Mohit Manrao, Senior Vice President, Head of US Oncology, AstraZeneca and President, AstraZeneca Foundation, emphasized the need for grassroots intervention. "We are in the golden era of cancer care, yet cancer screening and early detection rates for many types of cancer remain low, with significant disparities across zip codes," Manrao said. "Our partnership with Y-USA can directly reach millions of Americans at scale and at the grassroots level because every patient, regardless of zip code, deserves support throughout their cancer journey."

Suzanne McCormick, President and CEO, Y-USA, highlighted the complementary strengths of the two organizations. "We are bringing together AstraZeneca’s global expertise in life-changing innovations and the YMCA’s expansive community reach to transform our nation’s approach to cancer care," McCormick stated. "Over the next five years, we will expand screening, early detection, and survivorship programs to reach more people in the places they live and help them lead longer, healthier lives."

Context and Data

New data indicates that while people are living longer after a cancer diagnosis due to advances in treatment, more people are being diagnosed with the disease. A 2025 survey from the Prevent Cancer Foundation reveals that 51% of US adults aged 21 and older reported having a routine medical appointment or cancer screening in the last year, a 10% drop compared to its 2024 survey. However, 73% of those surveyed were more likely to schedule routine cancer screenings after learning about the benefits of early detection. The five-year survival rate for many types of cancer is almost 90% when found early.

AstraZeneca Plc received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer therapy Truqap gaining approval for a subset of prostate cancer patients and its kidney disease treatment Ultomiris receiving Priority Review for a new indication. The approvals strengthen the company's portfolio in oncology and rare diseases, addressing critical needs for patients with specific genetic profiles and conditions with limited treatment options.

Truqap Becomes First Targeted Option For PTEN-Deficient Prostate Cancer

The FDA approved Truqap (capivasertib) in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer. This approval makes the regimen the first and only targeted treatment available for this patient population when identified through an FDA-authorized test. The decision addresses a critical need for patients with this specific genetic profile, offering a new therapeutic option where previously none existed.

The FDA decision was supported by findings from the Phase III CAPItello-281 trial. Results showed a 19% reduction in the risk of radiographic disease progression or death compared with abiraterone and androgen deprivation therapy alone. Patients receiving the Truqap combination achieved a median radiographic progression-free survival (rPFS) of 33.2 months, versus 25.7 months in the comparator arm, representing an improvement of 7.5 months. The trial will continue to assess overall survival as a key secondary endpoint.

The safety profile of Truqap in combination with abiraterone and androgen deprivation therapy in CAPItello-281 was broadly consistent with the known profile of each medicine. Grade 3 or higher adverse events occurred in 67% of patients treated with the Truqap combination, with rash (12.3%) and hyperglycemia (10.3%) the most frequently reported. Concurrently with this approval, the FDA also approved a companion diagnostic test to detect PTEN deficiency in tumors of patients with prostate adenocarcinoma.

Ultomiris Receives Priority Review In IgA Nephropathy

Separately, the FDA accepted and granted Priority Review to a supplemental Biologics License Application for Ultomiris (ravulizumab) from AstraZeneca's Alexion rare disease division for the treatment of adults with immunoglobulin A nephropathy (IgAN). Priority Review is reserved for applications that may provide meaningful improvements over existing treatment options. The FDA's decision is expected during the fourth quarter of 2026.

The filing is based on interim Phase 3 I CAN trial data presented at the 2026 European Renal Association Congress. Ultomiris reduced the 24-hour urine protein creatinine ratio by 46.6% from baseline at week 34, compared with 5.6% for placebo, producing a placebo-adjusted treatment effect of 43.4%. Proteinuria reductions appeared as early as week 10 and were maintained through week 34. The treatment was generally well tolerated, with no new safety concerns reported.